New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
04:55 EDTBOTA, BOTA, BOTA, BOTA, IMGN, IMGN, IMGN, IMGN, ARRY, ARRY, ARRY, ARRY, OFIX, OFIX, OFIX, OFIX, CMN, CMN, CMN, CMN, MDCO, MDCO, MDCO, MDCO, TTHI, TTHI, TTHI, TTHI, INO, INO, INO, INO, CNAT, CNAT, CNAT, CNAT, Q, Q, Q, QJefferies to hold a conference
2014 Global Healthcare Conference to be held in New York on June 2-5.
News For BOTA;CNAT;INO;TTHI;MDCO;CMN;OFIX;ARRY;IMGN;Q From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
10:36 EDTINOInovio management to meet with Maxim
Subscribe for More Information
08:50 EDTARRYArray BioPharma participates in a conference call with JPMorgan
JPMorgan SMid Biotech Analyst Rama hosts a conference call with CEO Ron Squarer on June 5 at 1 pm.
08:37 EDTQJPMorgan life sciences analyst holds an analyst/industry conference call
Subscribe for More Information
May 28, 2015
09:24 EDTMDCOJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
06:04 EDTARRYArray BioPharma management to meet with Maxim
Meeting to be held in New York on May 28 hosted by Maxim.
May 27, 2015
14:12 EDTIMGNImmunoGen ASCO presentation could be 'turning point,' BBJ says
ImmunoGen CEO Dan Junius says the company's experimental ovarian cancer drug IMGN853, on which data will be presented this Saturday at the American Society of Clinical Oncology, or ASCO, meeting, is the company’s best shot at having a wholly-owned medicine on the market in coming years, according to Boston Business Journal. Reference Link
05:19 EDTINOInovio partners with GeneOne Life Science for MERS immunotherapy development
Inovio Pharmaceuticals announced it will advance its DNA vaccine for MERS, or Middle East Respiratory Syndrome, into a phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science. MERS is a respiratory disease caused by a coronavirus, which is related to the severe acute respiratory syndrome, or SARS, virus. Currently, MERS carries a 40% death rate; there is no vaccine or effective treatment for this virus. Inovio and GeneOne will conduct a phase I trial to evaluate the safety, tolerability and immunogenicity of Inovio's DNA-based MERS vaccine. The companies are currently conducting pre-IND activities and plan to start the clinical study before year end. GeneOne will conduct and fund the clinical study in return for milestone-based co-ownership of the immunotherapy. Upon successful completion of the study, the companies plan to jointly seek additional third party support and resources to further develop and commercialize this product. In preclinical tests, INO-4500 showed robust and durable immune responses. Animals vaccinated with INO-4500 generated strong neutralizing antibodies and robust CD8+ T cells to MERS antigens. These findings are vital given the importance of neutralizing antibodies in preventing infection and the role T cells play in clearing infection by killing cells that harbor the virus.
May 26, 2015
10:39 EDTMDCOThe Medicines Co. says data show remodeling effect of MDCO-216 on HDL
Subscribe for More Information
09:58 EDTQOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: L Brands (LB) upgraded to Conviction Buy from Buy at Goldman... Dollar General (DG) upgraded to Conviction Buy from Buy at Goldman... Accenture (ACN) upgraded to Outperform from Market Perform at Cowen... Expedia (EXPE) upgraded to Outperform from Market Perform at JMP Securities... The Fresh Market (TFM) upgraded to Neutral from Underperform at Longbow... Marvell (MRVL) upgraded to Overweight from Equal Weight at Morgan Stanley... Health Care REIT (HCN) upgraded to Buy from Neutral at Mizuho... Gold Fields (GFI) upgraded to Buy from Hold at HSBC... eBay (EBAY) upgraded to Buy from Hold at Axiom... CNOOC (CEO) upgraded to Neutral from Underweight at JPMorgan... Quintiles (Q) upgraded to Buy from Neutral at SunTrust... DCT Industrial (DCT) upgraded to Neutral from Underperform at Credit Suisse... Pebblebrook Hotel (PEB) upgraded to Outperform from Neutral at Credit Suisse... Fortinet (FTNT) upgraded to Buy from Hold at Needham... BB&T (BBT) upgraded to Buy from Neutral at Guggenheim... Hercules Technology (HTGC) upgraded to Outperform from Neutral at Macquarie... InterXion (INXN) upgraded to Buy from Hold at Stifel.
07:14 EDTQQuintiles upgraded on positive catalysts at SunTrust
Subscribe for More Information
07:02 EDTQQuintiles upgraded to Buy at SunTrust
Subscribe for More Information
06:22 EDTQQuintiles upgraded to Buy from Neutral at SunTrust
Subscribe for More Information
May 22, 2015
16:10 EDTINOInovio files $250M mixed securities shelf
Subscribe for More Information
May 21, 2015
08:39 EDTIMGNNovartis initiates Phase 1 PCA062, triggering milestone payment to ImmunoGen
In a regulatory filing, ImmunoGen disclosed Novartis (NVS) Institutes for BioMedical Research notified ImmunoGen (IMGN) that Novartis had initiated Phase I, first-in-human clinical testing of a product candidate, PCA062, utilizing antibody-drug conjugate technology. Pursuant to the license taken under our 2010 Multi-Target Agreement, this start of clinical testing triggers a $5M milestone payment to ImmunoGen.
May 20, 2015
10:11 EDTCNATConatus management to meet with SunTrust
Subscribe for More Information
06:55 EDTMDCOEagle Pharmaceuticals submits NDA for ready-to-use bivalirudin to FDA
Subscribe for More Information
May 19, 2015
07:28 EDTARRYUBS to hold a conference
Global Healthcare Conference is being held in New York on May 18-20 with webcasted company presentations to begin on May 19 at 8 am; not all company presentations may be webcasted. Webcast Link
06:52 EDTQQuintiles valuation attractive ahead of FY16 accelerating, says Credit Suisse
Subscribe for More Information
May 18, 2015
16:02 EDTOFIXOrthofix sees FY15 revenue $385M-$390M, consensus $390.1M
Subscribe for More Information
16:01 EDTOFIXOrthofix reports Q1 adjusted EPS (15c), may not compare to one estimate 8c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use